IBD research, Research institutes gastroenterology and liver, Iran
Shaghayegh Baradaran Ghavami is a dedicated researcher with over 10 years of expertise in immunology, microbiology, and molecular biology. Specializing in autoimmune diseases like Inflammatory Bowel Disease (IBD), her work focuses on innovative therapies such as probiotics, nanocomposites, and viral infection impacts on immune responses in autoimmune patients. She is highly skilled in advanced molecular techniques, including RNA/DNA extraction, flow cytometry, microbiological assays, and animal model studies. With a strong background in mentoring Master’s and Ph.D. students, she has contributed significantly to multiple high-impact publications. Passionate about advancing knowledge in immune-mediated diseases, Shaghayegh’s work has led to groundbreaking approaches in diagnostics and therapeutic development.
Profile
Education
Shaghayegh Baradaran Ghavami holds a Ph.D. in Microbiology from Azad University, Science and Research Branch, Tehran, Iran (2010-2015). Prior to that, she completed her M.Sc. in Microbiology at Islamic Azad University, North Tehran Branch, Iran (2008-2010). Her extensive academic background laid the foundation for her research in immunology and microbiology, specifically focusing on autoimmune diseases. Throughout her education, Shaghayegh demonstrated a commitment to deepening scientific understanding, leading her to pursue a career in both laboratory and clinical research, where she has made significant contributions to advancing medical practices and patient outcomes.
Experience
Shaghayegh Baradaran Ghavami has over a decade of experience in both clinical and academic research. She is currently a Postdoctoral Fellow at the Research Institute for Gastroenterology and Liver Disease at Shaheed Beheshti University of Medical Sciences (2018-2026), where she oversees research design, data analysis, and project dissemination. Previously, she served as a Clinical Research Fellow at the same institution (2016-2018), where she coordinated research teams and contributed to numerous publications. Additionally, she worked as a tutor at Azad University, Tehran, supporting students through complex microbiological concepts and promoting critical thinking. Her professional experience spans across experimental research, research proposal development, grant management, and academic mentoring.
Awards and Honors
Shaghayegh Baradaran Ghavami has received several prestigious recognitions in her research career. In 2020, she was awarded a $30,000 research grant from Orchid Life Company for her project on IBD and COVID-19. Her work has also earned her opportunities to present at major international conferences, such as the “Advanced Immunology 2023” congress in London and the “Microbiota MI 2020” meeting in Milan. Her research achievements are consistently acknowledged through citations in high-impact journals, showcasing her contributions to the fields of immunology and microbiology. Shaghayegh’s awards and honors reflect her dedication to advancing scientific knowledge and therapeutic innovations in autoimmune diseases.
Research Focus
Shaghayegh Baradaran Ghavami’s research is focused on advancing the understanding of immune-mediated diseases, particularly Inflammatory Bowel Disease (IBD). Her work explores the immunomodulatory effects of probiotics, the role of the gut microbiota, and the use of nanocomposite-based therapies to manage autoimmune diseases. She investigates the mechanisms underlying the interaction between viral infections and immune responses in IBD patients, providing insights into new therapeutic approaches. Shaghayegh’s research aims to develop novel diagnostic tools and interventions that can improve the quality of life for individuals suffering from autoimmune conditions. Her studies have contributed to enhancing the understanding of dendritic cells, immunological markers, and their potential as therapeutic targets for IBD.
Publication Top Notes
- “Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases” 📚🦠
- “Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory…” 🔬🧬
- “The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study” 🌏📊
- “Mesenchymal stem cell spheroids embedded in an injectable thermosensitive hydrogel: an in situ drug formation platform for accelerated wound healing” 🧫💉
- “Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease” 🦠🧘♀️
- “Cross-talk between immune system and microbiota in COVID-19” 🦠🌍
- “Overview of three proliferation pathways (Wnt, Notch, and Hippo) in intestine and immune system and their role in inflammatory bowel diseases (IBDs)” 🔬🧬
- “Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy” 💊🦠
- “Probiotic-induced tolerogenic dendritic cells: a novel therapy for inflammatory bowel disease?” 💉🔬
- “Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice” 🤔💊
- “The critical role of gut-brain axis microbiome in mental disorders” 🧠🌱